Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021)
Elicio Therapeutics' (ELTX) quarterly Gross Margin came in at 98.33% in Q4 2021, up 2578.0% on a YoY basis from 3.67% in Q4 2020, and down 1.67% quarter-over-quarter from 100.0% in Q3 2021.
Powered by 
Analysis
Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021) Analysis & Trends
Elicio Therapeutics (ELTX) has reported Gross Margin for 2 consecutive years, with 98.33% the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Gross Margin rose 2578.0% year-over-year to 98.33%; the trailing twelve-month figure through Dec 2021 stood at 98.47% (up 3979.0% YoY), and the FY2022 full-year result was 100.0%, up 153.0% from the prior year.
- Gross Margin declined to 98.33% in Q4 2021 per ELTX's latest filing, from 100.0% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q1 2021 and bottomed at 54.32% in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 80.31% |
| 10 | Elicio Therapeutics | 40.60 Mn | 17.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 98.33% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2020 | 72.55% |
| Sep 30, 2020 | 57.92% |
| Jun 30, 2020 | 54.32% |
| Mar 31, 2020 | 55.72% |